

Interactions with PBC Agents

Please note that if a drug is not listed it cannot automatically be assumed it is safe to coadminister.

BZF; Bezafibrate, ELA, Elafibranor; OCA, Obeticholic Acid; SEL, Seladelpar; UDCA, Ursodeoxycholic Acid

	BZF	ELA	OCA	SEL	UDCA
Anaesthetics & Muscle Relaxants					
Bupivacaine	◆	◆	◆	◆	◆
Cisatracurium	◆	◆	◆	◆	◆
Desflurane	◆	◆	◆	◆	◆
Dexmedetomidine	◆	▲	◆	◆	◆
Ephedrine	◆	◆	◆	◆	◆
Etidocaine	◆	◆	◆	◆	◆
Halothane	◆	◆	◆	◆	◆
Isoflurane	◆	◆	◆	◆	◆
Ketamine	◆	◆	◆	◆	◆
Nitrous oxide	◆	◆	◆	◆	◆
Propofol	◆	◆	◆	◆	◆
Remifentanyl	◆	◆	◆	◆	◆
Rocuronium	◆	◆	◆	◆	◆
Sevoflurane	◆	◆	◆	◆	◆
Tetracaine	◆	◆	◆	◆	◆
Thiopental	◆	◆	◆	◆	◆
Tizanidine	◆	◆	■	◆	▲
Analgesics					
Acetofenac	◆	◆	◆	◆	◆
Alfentanil	◆	◆	◆	◆	◆
Aspirin	◆	◆	◆	◆	◆
Buprenorphine	◆	▲	◆	◆	◆
Celecoxib	◆	◆	◆	◆	◆
Codeine	◆	◆	◆	◆	▲
Dexketoprofen	◆	◆	◆	◆	◆
Dextropropoxyphene	◆	◆	◆	◆	▲
Diamorphine	◆	▲	◆	◆	▲
Diclofenac	◆	◆	◆	▲	◆
Diflunisal	◆	◆	◆	◆	◆
Dihydrocodeine	◆	▲	◆	◆	▲
Etodolac	◆	◆	◆	◆	▲
Etoricoxib	◆	◆	▲	◆	◆
Fentanyl (Prescribed)	◆	◆	◆	◆	◆
Flurbiprofen	◆	▲	◆	◆	◆
Hydrocodone	◆	◆	◆	◆	▲
Hydromorphone	◆	◆	◆	◆	▲
Ibuprofen	◆	▲	◆	◆	◆
Indometacin	◆	▲	▲	◆	◆
Ketoprofen	◆	▲	◆	◆	◆
Mefenamic acid	◆	▲	◆	◆	◆
Meloxicam	◆	▲	▲	◆	◆
Metamizole (Dipyrone)	◆	◆	◆	◆	◆
Methadone	◆	◆	■	◆	▲
Morphine	◆	▲	◆	◆	◆
Naproxen	◆	▲	◆	▲	◆
Nefopam	◆	◆	◆	◆	◆
Oxycodone	◆	◆	◆	◆	▲
Paracetamol	◆	◆	◆	◆	◆
Pethidine (Meperidine)	◆	◆	◆	◆	▲
Piroxicam	◆	◆	◆	◆	◆
Tapentadol	◆	◆	◆	◆	▲
Tramadol	◆	◆	◆	◆	▲
Anthelmintics					
Albendazole	◆	◆	◆	◆	◆
Ivermectin	◆	◆	◆	◆	◆
Niclosamide	◆	◆	◆	◆	◆
Oxamniquine	◆	◆	◆	◆	◆
Praziquantel	◆	◆	▲	◆	◆
Pyrantel	◆	◆	◆	◆	◆
Antiarrhythmics					
Amiodarone	◆	◆	▲	■	▲
Bepidil	◆	◆	◆	◆	▲
Digoxin	◆	◆	◆	◆	◆
Disopyramide	◆	◆	◆	◆	◆
Dofetilide	◆	◆	◆	◆	▲
Dronedarone	◆	◆	▲	◆	▲
Flecainide	◆	◆	◆	◆	◆
Lidocaine (Lignocaine)	◆	◆	◆	◆	◆
Mexiletine	◆	◆	■	◆	▲
Propafenone	◆	◆	■	◆	▲
Quinidine	◆	◆	◆	◆	▲
Vernakalant	◆	◆	◆	◆	◆
Antibacterials					
Amikacin	◆	◆	◆	◆	◆
Amoxicillin	◆	◆	◆	◆	◆
Ampicillin	◆	◆	◆	◆	◆
Azithromycin	◆	◆	◆	◆	◆
Aztreonam	◆	◆	◆	◆	◆
Bedaquiline	◆	◆	◆	◆	◆
Benzylpenicillin	◆	◆	◆	◆	◆
Bezlotoxumab	◆	◆	◆	◆	◆
Capreomycin	◆	◆	◆	◆	◆
Cefaclor	◆	◆	◆	◆	◆
Cefadroxil	◆	◆	◆	◆	◆
Cefalexin	◆	◆	◆	◆	◆
Cefazolin	◆	◆	◆	◆	◆
Cefixime	◆	◆	◆	◆	◆

For personal use only. Not for distribution.

	BZF	ELA	OCA	SEL	UDCA
Antibacterials (continued)					
Cefotaxime	◆	◆	◆	◆	◆
Cefradine	◆	◆	◆	◆	◆
Ceftaroline	◆	◆	◆	◆	◆
Ceftazidime	◆	◆	◆	◆	◆
Ceftriaxone	◆	◆	◆	◆	◆
Cefuroxime	◆	◆	◆	◆	◆
Cefuroxime	◆	◆	◆	◆	◆
Chloramphenicol	◆	▲	◆	◆	◆
Ciprofloxacin	◆	◆	◆	◆	■
Clarithromycin	◆	◆	◆	◆	◆
Clavulanic acid	◆	◆	◆	◆	◆
Clindamycin	◆	◆	◆	◆	▲
Clofazimine	◆	◆	◆	◆	◆
Cloxacillin	◆	◆	◆	◆	◆
Cycloserine	◆	◆	◆	◆	◆
Dapsone	◆	◆	◆	◆	■
Daptomycin	■	◆	◆	◆	◆
Delamanid	◆	◆	◆	◆	◆
Ertapenem	◆	◆	◆	◆	◆
Erythromycin	■	◆	■	◆	◆
Ethambutol	◆	◆	◆	◆	◆
Flucloxacillin	◆	◆	◆	◆	◆
Fosfomycin	◆	◆	◆	◆	◆
Gatifloxacin (topical)	◆	◆	◆	◆	◆
Gentamicin	◆	◆	◆	◆	◆
Imipenem	◆	◆	◆	◆	◆
Isoniazid	◆	◆	▲	◆	◆
Levofloxacin	◆	◆	◆	◆	◆
Linezolid	●	◆	◆	◆	▲
Lymecycline	◆	◆	◆	◆	◆
Meropenem	◆	◆	◆	◆	◆
Methenamine	◆	◆	◆	◆	◆
Metronidazole	◆	◆	◆	◆	◆
Minocycline	◆	◆	◆	◆	◆
Moxifloxacin	◆	◆	◆	◆	◆
Nitrofurantoin	◆	◆	◆	◆	◆
Norfloxacin	◆	◆	◆	◆	◆
Ofloxacin	◆	◆	◆	◆	◆
Penicillin V	◆	◆	◆	◆	◆
Piperacillin	◆	◆	◆	◆	◆
Pivmecillinam	◆	◆	◆	◆	◆
Pretomanid	◆	◆	◆	■	▲
Pyrazinamide	◆	◆	◆	◆	◆
Rifabutin	◆	◆	▲	■	▲
Rifampicin	◆	■	◆	■	▲
Rifapentine	◆	■	■	■	▲
Rifaximin	◆	◆	◆	◆	◆
Spectinomycin	◆	◆	◆	◆	◆
Streptomycin	◆	◆	◆	◆	◆
Sulfadiazine	◆	◆	◆	◆	◆
Tazobactam	◆	◆	◆	◆	◆
Telithromycin	◆	◆	■	◆	◆
Temocillin	◆	◆	◆	◆	◆
Tetracyclines	◆	◆	◆	◆	◆
Ticarcillin	◆	◆	◆	◆	◆
Tobramycin	◆	◆	◆	◆	◆
Trimethoprim/Sulfamethoxazole	◆	◆	◆	◆	◆
Troleandomycin	◆	◆	◆	◆	◆
Vancomycin	◆	◆	◆	◆	◆
Anticoagulant, Antiplatelet & Fibrinolytic					
Abciximab	◆	◆	◆	◆	◆
Acenocoumarol	■	◆	▲	◆	▲
Anagrelide	◆	◆	◆	◆	▲
Apixaban	◆	◆	◆	◆	▲
Caplacizumab	◆	◆	◆	◆	▲
Clopidogrel	◆	▲	▲	◆	◆
Dabigatran	◆	◆	◆	■	▲
Dalteparin	◆	◆	◆	◆	◆
Danaparoid	◆	◆	◆	◆	◆
Dipyridamole	◆	◆	■	◆	◆
Edoxaban	◆	◆	◆	◆	▲
Eltrombopag	◆	◆	◆	■	◆
Enoxaparin	◆	◆	◆	◆	◆
Fluindione	◆	◆	▲	◆	▲
Fondaparinux	◆	◆	◆	◆	◆
Heparin	◆	◆	◆	◆	◆
Natalizumab	◆	◆	◆	◆	◆
Phenprocoumon	■	◆	◆	◆	▲
Prasugrel	◆	◆	◆	◆	◆
Rivaroxaban	◆	◆	◆	◆	▲
Streptokinase	◆	◆	◆	◆	◆
Ticagrelor	◆	◆	◆	◆	◆
Ticlopidine	◆	◆	◆	◆	◆
Tinzaparin	◆	◆	◆	◆	◆
Warfarin	■	◆	■	◆	▲

For personal use only. Not for distribution.

Key to symbols

●	These drugs should not be coadministered
■	Potential clinically significant interaction that is likely to require additional monitoring, alteration of drug dosage or timing of administration
▲	Potential interaction likely to be of weak intensity. Additional action/monitoring or dosage adjustment is unlikely to be required
◆	No clinically significant interaction expected

Notes

- Further information is available at www.hep-druginteractions.org
- Predicted interactions are based on known metabolic pathways and routes of clearance.
- Caution is required in patients with hepatic impairment as this may also increase drug levels and require dose modification.
- Where advice differs between countries, the charts reflect the more cautious option.

© Liverpool Drug Interactions Group, Liverpool Drug Interactions Group, University of Liverpool, 3rd Floor William Henry Duncan Building, 6 West Derby Street, Liverpool, L7 8TX.
 We aim to ensure that information is accurate and consistent with current knowledge and practice. However, the University of Liverpool and its servants or agents shall not be responsible or in any way liable for the continued currency of information in this publication whether arising from negligence or otherwise howsoever or for any consequences arising therefrom. The University of Liverpool expressly exclude liability for errors, omissions or inaccuracies to the fullest extent permitted by law.

Interactions with PBC Agents

Please note that if a drug is not listed it cannot automatically be assumed it is safe to coadminister.

BZF; Bezafibrate, ELA, Elafibranor; OCA, Obeticholic Acid; SEL, Seladelpar; UDCA, Ursodeoxycholic Acid

	BZF	ELA	OCA	SEL	UDCA
Anticonvulsants					
Brivaracetam	◆	◆	◆	▲	◆
Carbamazepine	◆	■	◆	■	▲
Clonazepam	◆	◆	◆	◆	◆
Eslicarbazepine	◆	◆	◆	■	◆
Ethosuximide	◆	◆	◆	◆	◆
Gabapentin	◆	◆	◆	◆	◆
Lacosamide	◆	◆	◆	◆	◆
Lamotrigine	◆	▲	◆	◆	◆
Levetiracetam	◆	◆	◆	◆	◆
Oxcarbazepine	◆	◆	◆	■	◆
Perampanel	◆	◆	◆	◆	◆
Phenobarbital	◆	■	◆	■	▲
Phenytoin	◆	■	◆	■	▲
Pregabalin	◆	◆	◆	◆	◆
Primidone	◆	■	◆	■	◆
Retigabine	◆	◆	◆	◆	◆
Rufinamide	◆	◆	◆	◆	◆
Sultiame	◆	◆	◆	◆	◆
Tiagabine	◆	◆	◆	◆	◆
Topiramate	◆	◆	◆	◆	◆
Valproic acid	◆	▲	◆	◆	◆
Vigabatrin	◆	◆	◆	◆	◆
Zonisamide	◆	◆	◆	◆	◆
Antidepressants					
Agomelatine	◆	◆	▲	◆	◆
Amitriptyline	◆	◆	◆	◆	▲
Bupropion	◆	◆	◆	◆	◆
Citalopram	◆	◆	◆	◆	◆
Clomipramine	◆	◆	◆	◆	▲
Desipramine	◆	◆	◆	◆	▲
Desvenlafaxine	◆	◆	◆	◆	▲
Dosulepin	◆	◆	◆	◆	▲
Doxepin	◆	◆	◆	◆	▲
Duloxetine	◆	◆	◆	◆	◆
Escitalopram	◆	◆	◆	◆	◆
Fluoxetine	◆	◆	◆	◆	◆
Fluvoxamine	◆	◆	◆	■	◆
Imipramine	◆	◆	◆	◆	▲
Lithium	◆	◆	◆	◆	◆
Maprotiline	◆	◆	◆	◆	▲
Mianserin	◆	◆	◆	◆	◆
Milnacipran	◆	◆	◆	◆	◆
Mirtazapine	◆	◆	◆	◆	▲
Moclobemide	▲	◆	◆	◆	◆
Nefazodone	◆	◆	■	◆	◆
Nortriptyline	◆	◆	◆	◆	▲
Opipramol	◆	◆	◆	◆	◆
Paroxetine	◆	◆	◆	◆	◆
Phenelzine	●	●	●	●	●
Reboxetine	◆	◆	◆	◆	◆
Sertraline	◆	◆	◆	◆	◆
Tianeptine	◆	◆	◆	◆	◆
Trazodone	◆	◆	◆	◆	◆
Trimipramine	◆	◆	◆	◆	▲
Venlafaxine	◆	◆	◆	◆	◆
Vortioxetine	◆	◆	◆	◆	◆
Antidiabetics					
Acarbose	■	◆	◆	◆	◆
Albiglutide	■	◆	◆	◆	◆
Alogliptin	■	◆	◆	◆	◆
Canagliflozin	■	◆	◆	◆	◆
Dapagliflozin	■	◆	◆	◆	◆
Dulaglutide	■	◆	◆	◆	◆
Empagliflozin	■	▲	◆	◆	◆
Exenatide	■	◆	◆	◆	◆
Glibenclamide (Glyburide)	■	◆	■	◆	▲
Gliclazide	■	◆	◆	◆	◆
Glimepiride	■	◆	■	◆	▲
Glipizide	■	◆	◆	◆	▲
Insulin	■	◆	◆	◆	◆
Linagliptin	■	◆	◆	◆	◆
Liraglutide	■	◆	◆	◆	◆
Lixisenatide	■	◆	◆	◆	◆
Metformin	■	◆	◆	◆	◆
Nateglinide	■	◆	◆	◆	◆
Pioglitazone	■	◆	▲	◆	◆
Repaglinide	■	◆	▲	◆	◆
Rosiglitazone	■	◆	■	◆	◆
Saxagliptin	■	◆	◆	◆	◆
Semaglutide	■	◆	◆	◆	◆
Sitagliptin	■	◆	◆	◆	◆
Tirzepatide	■	◆	◆	◆	◆
Tolbutamide	■	◆	◆	◆	▲
Vildagliptin	■	◆	◆	◆	◆

For personal use only. Not for distribution.

	BZF	ELA	OCA	SEL	UDCA
Antifungals					
Amphotericin B	◆	◆	◆	◆	◆
Anidulafungin	◆	◆	◆	◆	◆
Caspofungin	◆	◆	◆	◆	◆
Clotrimazole (pessary)	◆	◆	◆	◆	◆
Clotrimazole (topical)	◆	◆	◆	◆	◆
Fluconazole	◆	◆	◆	■	◆
Flucytosine	◆	◆	◆	◆	◆
Griseofulvin	◆	◆	◆	◆	◆
Isavuconazole	◆	◆	◆	▲	◆
Itraconazole	◆	◆	■	◆	▲
Ketoconazole	◆	◆	■	◆	▲
Miconazole	◆	◆	■	◆	◆
Nystatin	◆	◆	◆	◆	◆
Posaconazole	◆	◆	■	◆	▲
Terbinafine	◆	◆	◆	◆	◆
Voriconazole	◆	◆	◆	■	▲
Antithaemorrhagics					
Avatrombopag	◆	◆	◆	●	▲
Eltrombopag	◆	◆	◆	◆	◆
Tranexamic acid	◆	◆	◆	◆	◆
Antihistamines					
Astemizole	◆	◆	▲	◆	▲
Bilastine	◆	◆	◆	◆	◆
Cetirizine	◆	◆	◆	◆	◆
Chlorphenamine	◆	◆	◆	◆	▲
Clemastine	◆	◆	◆	◆	◆
Desloratadine	◆	◆	◆	◆	◆
Diphenhydramine	◆	◆	◆	◆	◆
Doxylamine	◆	◆	■	◆	◆
Ebastine	◆	◆	◆	◆	◆
Fexofenadine	◆	◆	◆	◆	◆
Hydroxyzine	◆	◆	■	◆	◆
Levocetirizine	◆	◆	◆	◆	◆
Loratadine	◆	◆	■	◆	◆
Promethazine	◆	◆	◆	◆	◆
Terfenadine	◆	◆	◆	◆	▲
Antimigraine Agents					
Almotriptan	◆	◆	◆	◆	◆
Dihydroergotamine	◆	◆	◆	◆	◆
Eletriptan	◆	◆	◆	◆	◆
Eptinezumab	◆	◆	◆	◆	◆
Ergotamine	◆	◆	◆	◆	▲
Fremanezumab	◆	◆	◆	◆	◆
Frovatriptan	◆	◆	◆	◆	◆
Galcanezumab	◆	◆	◆	◆	◆
Methylergonovine	◆	◆	◆	◆	▲
Naratriptan	◆	◆	◆	◆	◆
Pizotifen	◆	◆	◆	◆	◆
Rizatriptan	◆	◆	◆	◆	◆
Sumatriptan	◆	◆	◆	◆	◆
Zolmitriptan	◆	◆	■	◆	◆
Antiprotozoals					
Amodiaquine	◆	◆	◆	◆	▲
Artemether	◆	◆	◆	◆	◆
Artemisinin	◆	▲	◆	◆	◆
Artesunate	◆	▲	◆	◆	◆
Atovaquone	◆	◆	◆	◆	▲
Chloroquine	■	◆	◆	◆	▲
Dihydroartemisinin	◆	▲	◆	◆	◆
Doxycycline	◆	◆	◆	◆	◆
Halofantrine	◆	◆	◆	◆	▲
Hydroxychloroquine	■	◆	◆	◆	◆
Lumefantrine	◆	◆	◆	◆	◆
Mefloquine	◆	◆	◆	◆	◆
Nitazoxanide	◆	◆	◆	◆	◆
Pentamidine	◆	◆	▲	◆	◆
Primaquine	◆	◆	◆	◆	◆
Proguanil	◆	◆	◆	◆	◆
Pyrimethamine	◆	◆	◆	◆	▲
Quinine	◆	◆	◆	◆	▲
Sodium stibogluconate	◆	◆	◆	◆	◆
Sulfadoxine	◆	◆	◆	◆	◆

For personal use only. Not for distribution.

Key to symbols

●	These drugs should not be coadministered
■	Potential clinically significant interaction that is likely to require additional monitoring, alteration of drug dosage or timing of administration
▲	Potential interaction likely to be of weak intensity. Additional action/monitoring or dosage adjustment is unlikely to be required
◆	No clinically significant interaction expected

Notes

- Further information is available at www.hep-druginteractions.org
- Predicted interactions are based on known metabolic pathways and routes of clearance.
- Caution is required in patients with hepatic impairment as this may also increase drug levels and require dose modification.
- Where advice differs between countries, the charts reflect the more cautious option.

© Liverpool Drug Interactions Group,
 Liverpool Drug Interactions Group, University of Liverpool, 3rd Floor William Henry Duncan Building, 6 West Derby Street, Liverpool, L7 8TX.
 We aim to ensure that information is accurate and consistent with current knowledge and practice. However, the University of Liverpool and its servants or agents shall not be responsible or in any way liable for the continued currency of information in this publication whether arising from negligence or otherwise howsoever or for any consequences arising therefrom. The University of Liverpool expressly exclude liability for errors, omissions or inaccuracies to the fullest extent permitted by law.

Interactions with PBC Agents

Please note that if a drug is not listed it cannot automatically be assumed it is safe to coadminister.

BZF; Bezaifibrate, ELA, Elafibranol; OCA, Obeticholic Acid; SEL, Seladelpar; UDCA, Ursodeoxycholic Acid

	BZF	ELA	OCA	SEL	UDCA
Antipsychotics/Neuroleptics					
Amisulpride	◆	◆	◆	◆	◆
Aripiprazole	◆	◆	◆	◆	◆
Asenapine	◆	◆	▲	◆	◆
Brexiprazole	◆	◆	◆	◆	▲
Cariprazine	◆	◆	◆	◆	▲
Chlorpromazine	◆	◆	◆	◆	◆
Chlorprothixene	◆	◆	◆	◆	▲
Clozapine	◆	◆	■	◆	◆
Flupentixol	◆	◆	◆	◆	▲
Fluphenazine	◆	◆	▲	◆	◆
Haloperidol	◆	▲	◆	◆	▲
Iloperidone	◆	◆	▲	◆	▲
Levomepromazine	◆	◆	◆	◆	◆
Loxapine	◆	◆	◆	◆	◆
Lurasidone	◆	◆	◆	◆	◆
Olanzapine	◆	◆	■	◆	◆
Paliperidone	◆	◆	◆	◆	▲
Perazine	◆	◆	◆	◆	◆
Periciazine	◆	◆	◆	◆	◆
Perphenazine	◆	◆	◆	◆	◆
Pimozide	◆	◆	◆	◆	▲
Pipotiazine	◆	◆	◆	◆	◆
Prochlorperazine	◆	◆	◆	◆	◆
Promazine	◆	◆	◆	◆	▲
Quetiapine	◆	◆	◆	◆	◆
Risperidone	◆	◆	◆	◆	◆
Sulpiride	◆	◆	◆	◆	◆
Tiapride	◆	◆	◆	◆	◆
Trifluoperazine	◆	◆	◆	◆	◆
Ziprasidone	◆	◆	◆	◆	◆
Zuclopentixol	◆	◆	◆	◆	▲
Antivirals					
Aciclovir	◆	◆	◆	◆	◆
Amantadine	◆	◆	◆	◆	◆
Ansuvimab	◆	◆	◆	◆	◆
Brincidofovir	◆	◆	◆	■	◆
Brivudine	◆	◆	◆	◆	◆
Cidofovir	◆	◆	◆	◆	◆
Favipiravir	◆	◆	◆	▲	◆
Foscarnet	◆	◆	◆	◆	◆
Molnupiravir	◆	◆	◆	◆	◆
Nirmatrelvir/ritonavir	◆	◆	◆	■	◆
Oseltamivir	◆	◆	◆	◆	◆
Remdesivir	◆	◆	◆	◆	◆
Rimantadine	◆	◆	◆	◆	◆
Sotrovimab	◆	◆	◆	◆	◆
Tecovirimat	◆	▲	◆	◆	◆
Tixagevimab/cilgavimab	◆	◆	◆	◆	◆
Valaciclovir	◆	◆	◆	◆	◆
Zanamivir	◆	◆	◆	◆	◆
Anxiolytics/Hypnotics/Sedatives					
Alprazolam	◆	◆	◆	◆	◆
Amobarbital	◆	■	◆	◆	▲
Bromazepam	◆	◆	◆	◆	◆
Bromperidol	◆	◆	◆	◆	◆
Buspirone	◆	◆	◆	◆	◆
Chlordiazepoxide	◆	◆	◆	◆	◆
Clobazam	◆	◆	◆	◆	◆
Clorazepate	◆	◆	◆	◆	◆
Clotiapine	◆	◆	◆	◆	◆
Daridorexant	◆	■	◆	▲	▲
Diazepam	◆	◆	◆	◆	◆
Estazolam	◆	◆	◆	◆	◆
Flurazepam	◆	◆	◆	◆	◆
Lemborexant	◆	◆	◆	◆	◆
Lorazepam	◆	◆	◆	◆	◆
Lormetazepam	◆	◆	◆	◆	◆
Midazolam (oral)	◆	◆	▲	◆	◆

For personal use only. Not for distribution.

	BZF	ELA	OCA	SEL	UDCA
Anxiolytics/Hypnotics/Sedatives continued					
Midazolam (parenteral)	◆	◆	▲	◆	◆
Oxazepam	◆	◆	◆	◆	◆
Quazepam	◆	◆	◆	◆	◆
Temazepam	◆	◆	◆	◆	◆
Triazolam	◆	◆	◆	◆	◆
Zaleplon	◆	◆	◆	◆	◆
Zolpidem	◆	◆	◆	◆	◆
Zopiclone	◆	◆	◆	◆	◆
Beta Blockers					
Atenolol	◆	◆	◆	◆	◆
Bisoprolol	◆	◆	◆	◆	◆
Carvedilol	◆	▲	◆	◆	▲
Celiprolol	◆	◆	◆	◆	▲
Labetalol	◆	▲	◆	◆	▲
Metoprolol	◆	◆	◆	◆	◆
Nebivolol	◆	◆	◆	◆	▲
Oxprenolol	◆	◆	◆	◆	◆
Pindolol	◆	◆	◆	◆	◆
Propranolol	◆	◆	◆	◆	▲
Sotalol	◆	◆	◆	◆	◆
Timolol	◆	◆	◆	◆	▲
Bisphosphonates					
Alendronic acid	◆	◆	◆	◆	◆
Clodronate	◆	◆	◆	◆	◆
Ibandronic acid	◆	◆	◆	◆	◆
Pamidronate	◆	◆	◆	◆	◆
Risedronate	◆	◆	◆	◆	◆
Zoledronic acid	◆	◆	◆	◆	◆
Bronchodilators					
Acidinium bromide	◆	◆	◆	◆	◆
Aminophylline	◆	◆	◆	◆	◆
Formoterol	◆	◆	◆	◆	◆
Indacaterol	◆	◆	◆	◆	◆
Ipratropium bromide	◆	◆	◆	◆	◆
Montelukast	◆	◆	◆	◆	◆
Omalizumab	◆	◆	◆	◆	◆
Reslizumab	◆	◆	◆	◆	◆
Salbutamol	◆	◆	◆	◆	◆
Salmeterol	◆	◆	◆	◆	◆
Theophylline	◆	◆	■	◆	◆
Tiotropium	◆	◆	◆	◆	◆
Umeclidinium bromide	◆	◆	◆	◆	◆
Vilanterol	◆	◆	◆	◆	◆
Calcium Channel Blockers					
Amlodipine	◆	◆	◆	◆	▲
Diltiazem	◆	◆	◆	◆	▲
Felodipine	◆	◆	▲	◆	▲
Nicardipine	◆	◆	■	■	▲
Nifedipine	◆	◆	▲	◆	▲
Nisoldipine	◆	◆	▲	◆	▲
Nitrendipine	◆	◆	▲	◆	■
Verapamil	◆	◆	◆	◆	▲

For personal use only. Not for distribution.

Key to symbols

●	These drugs should not be coadministered
■	Potential clinically significant interaction that is likely to require additional monitoring, alteration of drug dosage or timing of administration
▲	Potential interaction likely to be of weak intensity. Additional action/monitoring or dosage adjustment is unlikely to be required
◆	No clinically significant interaction expected

Notes

- Further information is available at www.hep-druginteractions.org
- Predicted interactions are based on known metabolic pathways and routes of clearance.
- Caution is required in patients with hepatic impairment as this may also increase drug levels and require dose modification.
- Where advice differs between countries, the charts reflect the more cautious option.

© Liverpool Drug Interactions Group, Liverpool Drug Interactions Group, University of Liverpool, 3rd Floor William Henry Duncan Building, 6 West Derby Street, Liverpool, L7 8TX.
 We aim to ensure that information is accurate and consistent with current knowledge and practice. However, the University of Liverpool and its servants or agents shall not be responsible or in any way liable for the continued currency of information in this publication whether arising from negligence or otherwise howsoever or for any consequences arising therefrom. The University of Liverpool expressly exclude liability for errors, omissions or inaccuracies to the fullest extent permitted by law.

Interactions with PBC Agents

Charts updated April 2026. Full information available at www.hep-druginteractions.org

Please note that if a drug is not listed it cannot automatically be assumed it is safe to coadminister.

BZF; Bezafibrate, ELA, Elafibranor; OCA, Obeticholic Acid; SEL, Seladelpar; UDCA, Ursodeoxycholic Acid

Cancer Therapies	BZF	ELA	OCA	SEL	UDCA
Abiraterone	◆	◆	◆	◆	◆
Acalabrutinib	◆	◆	◆	◆	▲
Afatinib	◆	◆	◆	◆	◆
Alectinib	■	◆	◆	■	▲
Alpelisib	◆	◆	◆	◆	◆
Amivantamab	◆	◆	◆	◆	◆
Anastrozole	◆	◆	◆	◆	◆
Apalutamide	◆	■	◆	■	▲
Asciminib	◆	▲	◆	■	◆
Asparaginase	◆	◆	◆	◆	◆
Atezolizumab	■	◆	◆	◆	◆
Avapritinib	■	◆	▲	■	◆
Avelumab	◆	◆	◆	◆	◆
Axitinib	◆	◆	◆	◆	◆
Azacitidine	■	◆	◆	◆	◆
Belantamab mafodotin	◆	◆	◆	◆	◆
Bendamustine	◆	◆	◆	◆	◆
Bevacizumab	◆	◆	◆	◆	◆
Bexarotene	■	◆	◆	■	▲
Bicalutamide	◆	◆	◆	◆	◆
Binimetinib	■	◆	◆	▲	▲
Blinatumomab	◆	◆	◆	◆	◆
Bortezomib	◆	◆	◆	◆	◆
Bosutinib	◆	◆	◆	◆	◆
Brentuximab vedotin	◆	◆	◆	◆	◆
Brigatinib	■	■	◆	■	▲
Capecitabine	◆	◆	◆	■	◆
Capmatinib	◆	◆	◆	■	▲
Carboplatin	◆	◆	◆	◆	◆
Carfilzomib	◆	◆	◆	◆	◆
Cedazuridine	◆	◆	◆	◆	◆
Ceritinib	◆	◆	◆	■	▲
Cetuximab	◆	◆	◆	◆	◆
Chlorambucil	◆	◆	◆	◆	▲
Cisplatin	◆	◆	◆	◆	◆
Cladribine (IV)	◆	◆	◆	◆	◆
Cobimetinib	■	▲	◆	◆	▲
Crizotinib	◆	◆	◆	◆	◆
Cyclophosphamide	◆	◆	◆	◆	◆
Cytarabine	■	◆	◆	◆	◆
Dabrafenib	◆	■	◆	■	▲
Daratumumab	◆	◆	◆	◆	◆
Dasatinib	◆	◆	■	◆	◆
Decitabine	◆	◆	◆	◆	◆
Doxorubicin	◆	◆	◆	◆	◆
Durvalumab	◆	◆	◆	◆	◆
Elotuzumab	◆	◆	◆	◆	◆
Elranatamab	◆	◆	◆	◆	◆
Encorafenib	■	◆	◆	■	▲
Enzalutamide	◆	■	◆	■	▲
Epcoritamab	◆	◆	◆	◆	◆
Epirubicin	◆	▲	◆	◆	◆
Erlotinib	◆	◆	◆	◆	▲
Estramustine	◆	◆	◆	◆	▲
Etoposide	◆	◆	◆	◆	◆
Everolimus	◆	◆	■	◆	▲
Exemestane	◆	◆	▲	◆	◆
Fludarabine	◆	◆	◆	◆	◆
Fluorouracil (5-FU)	◆	◆	◆	■	◆
Gefitinib	◆	◆	■	■	◆
Gemcitabine	◆	◆	◆	◆	◆
Gemtuzumab ozogamicin	◆	◆	◆	◆	◆
Glofitamab	◆	◆	◆	◆	◆
Hydroxyurea (Hydroxycarbamide)	◆	◆	◆	◆	◆
Ibrutinib	◆	◆	◆	◆	▲

For personal use only. Not for distribution.

Cancer Therapies continued	BZF	ELA	OCA	SEL	UDCA
Idarubicin	◆	◆	◆	◆	▲
Idelalisib	◆	◆	◆	◆	▲
Imatinib	◆	◆	▲	■	◆
Inotuzumab ozogamicin	◆	◆	◆	◆	◆
Ipilimumab	◆	◆	◆	◆	◆
Irinotecan	◆	◆	◆	◆	◆
Isatuximab	◆	◆	◆	◆	◆
Ixazomib	◆	◆	◆	◆	◆
Lapatinib	◆	■	■	■	◆
Letrozole	◆	◆	◆	◆	◆
Loncastuximab tesirine	◆	◆	◆	◆	◆
Medroxyprogesterone (oncology)	◆	◆	■	◆	■
Mercaptopurine	◆	◆	◆	◆	◆
Mesna	◆	◆	◆	◆	◆
Methotrexate	◆	◆	◆	◆	◆
Mitoxantrone	◆	■	◆	◆	◆
Mogamulizumab	◆	◆	◆	◆	◆
Nilotinib	◆	◆	◆	■	◆
Niraparib	◆	◆	◆	◆	◆
Nivolumab	◆	◆	◆	◆	◆
Obinutuzumab	◆	◆	◆	◆	◆
Ofatumumab	◆	◆	◆	◆	◆
Olaparib	◆	◆	◆	▲	◆
Olaratumab	◆	◆	◆	◆	◆
Osimertinib	◆	◆	◆	▲	▲
Oxaliplatin	◆	◆	◆	◆	◆
Pacitaxel	◆	◆	▲	◆	◆
Panitumumab	◆	◆	◆	◆	◆
Panobinostat	◆	◆	◆	◆	▲
Pertuzumab	◆	◆	◆	◆	◆
Polatuzumab vedotin	◆	◆	◆	◆	◆
Pomalidomide	◆	◆	◆	◆	◆
Ponatinib	◆	◆	◆	◆	◆
Ramucirumab	◆	◆	◆	◆	◆
Retifanlimab	◆	◆	◆	◆	◆
Ribociclib	◆	◆	▲	■	◆
Rituximab	◆	◆	◆	◆	◆
Rucaparib	◆	◆	▲	■	◆
Ruxolitinib	◆	◆	◆	■	◆
Sacituzumab govitecan	◆	◆	◆	◆	◆
Selpercatinib	◆	◆	◆	▲	▲
Sotorasib	◆	◆	◆	◆	▲
Sunitinib	◆	■	▲	■	▲
Talazoparib	◆	◆	◆	◆	◆
Tamoxifen	◆	◆	◆	◆	◆
Tegafur/Gimeracil/Oteracil	◆	◆	◆	■	◆
Temsirolimus	◆	◆	■	◆	◆
Tepotinib	◆	◆	◆	▲	◆
Thioguanine	◆	◆	◆	◆	◆
Tisotumab vedotin	◆	◆	◆	◆	◆
Tivozanib	◆	◆	◆	▲	◆
Topotecan (IV)	◆	◆	◆	▲	◆
Topotecan (oral)	◆	■	◆	▲	◆
Trametinib	■	◆	◆	◆	◆
Trastuzumab	◆	◆	◆	◆	◆
Trastuzumab deruxtecan	◆	◆	◆	◆	◆
Trastuzumab emtansine	◆	◆	◆	◆	◆
Trifluridine/tipiracil	◆	◆	◆	◆	◆
Venetoclax	◆	■	◆	◆	◆
Vinblastine	◆	◆	◆	◆	◆
Vincristine	◆	◆	◆	◆	◆
Vinorelbine	◆	◆	◆	◆	◆
Zolbetuximab	◆	◆	◆	◆	◆

For personal use only. Not for distribution.

Key to symbols

●	These drugs should not be coadministered
■	Potential clinically significant interaction that is likely to require additional monitoring, alteration of drug dosage or timing of administration
▲	Potential interaction likely to be of weak intensity. Additional action/monitoring or dosage adjustment is unlikely to be required
◆	No clinically significant interaction expected

Notes

- Further information is available at www.hep-druginteractions.org
- Predicted interactions are based on known metabolic pathways and routes of clearance.
- Caution is required in patients with hepatic impairment as this may also increase drug levels and require dose modification.
- Where advice differs between countries, the charts reflect the more cautious option.

© Liverpool Drug Interactions Group,
 Liverpool Drug Interactions Group, University of Liverpool, 3rd Floor William Henry Duncan Building, 6 West Derby Street, Liverpool, L7 8TX.
 We aim to ensure that information is accurate and consistent with current knowledge and practice. However, the University of Liverpool and its servants or agents shall not be responsible or in any way liable for the continued currency of information in this publication whether arising from negligence or otherwise howsoever or for any consequences arising therefrom. The University of Liverpool expressly exclude liability for errors, omissions or inaccuracies to the fullest extent permitted by law.

Interactions with PBC Agents

Please note that if a drug is not listed it cannot automatically be assumed it is safe to coadminister.

BZF; Bezafibrate, ELA, Elafibanor; OCA, Obeticholic Acid; SEL, Seladelpar; UDCA, Ursodeoxycholic Acid

	BZF	ELA	OCA	SEL	UDCA
Contraceptives and Hormone Replacements					
Conjugated estrogens (HRT)	◆	◆	■	◆	■
Desogestrel (POP)	◆	■	◆	◆	■
Desogestrel/ethinylestradiol (COC) (>20 µg)	◆	■	■	◆	■
Desogestrel/ethinylestradiol (COC) (≤20 µg)	◆	■	■	◆	■
Dienogest	◆	◆	◆	◆	■
Drospirenone (POP)	◆	■	■	◆	■
Drospirenone/estradiol (HRT)	◆	◆	■	◆	■
Drospirenone/ethinylestradiol (COC) (>20 µg)	◆	■	■	◆	■
Drospirenone/ethinylestradiol (COC) (≤20 µg)	◆	■	■	◆	■
Hydrogesterone/estradiol (HRT)	◆	◆	◆	◆	■
Estradiol	◆	◆	◆	◆	■
Ethinylestradiol (>20 µg)	◆	■	■	◆	■
Ethinylestradiol (≤20 µg)	◆	■	■	◆	■
Etonogestrel (implant)	◆	■	◆	◆	■
Etonogestrel (vaginal ring)	◆	■	◆	◆	■
Gestodene/ethinylestradiol (COC) (>20 µg)	◆	■	■	◆	■
Gestodene/ethinylestradiol (COC) (≤20 µg)	◆	■	■	◆	■
Levonorgestrel (Emergency Contraception)	◆	■	◆	◆	◆
Levonorgestrel (HRT)	◆	◆	◆	◆	■
Levonorgestrel (implant)	◆	◆	◆	◆	■
Levonorgestrel (IUD)	◆	◆	◆	◆	◆
Levonorgestrel (POP)	◆	■	◆	◆	■
Levonorgestrel/ethinylestradiol (COC) (>20 µg)	◆	■	■	◆	■
Levonorgestrel/ethinylestradiol (COC) (≤20 µg)	◆	■	■	◆	■
Medroxyprogesterone (depot)	◆	■	■	◆	■
Medroxyprogesterone (oral)	◆	◆	■	◆	■
Medroxyprogesterone/conjugated estrogens (HRT)	◆	◆	■	◆	■
Medroxyprogesterone/estradiol (HRT)	◆	◆	■	◆	■
Micronized progesterone (HRT)	◆	◆	◆	◆	◆
Norelgestromin/ethinylestradiol (patch)	◆	■	■	◆	■
Norethisterone (Norethindrone) (depot injection)	◆	■	▲	◆	■
Norethisterone (Norethindrone) (POP)	◆	■	▲	◆	■
Norethisterone (Norethindrone)/estradiol (HRT)	◆	◆	▲	◆	■
Norethisterone (Norethindrone) ethinylestradiol (COC)	◆	■	■	◆	■
Norethisterone (Norethindrone)/mestranol (COC)	◆	■	■	◆	■
Norgestimate/ethinylestradiol (COC)	◆	■	■	◆	■
Norgestrel/conjugated estrogens (HRT)	◆	◆	■	◆	■
Norgestrel/ethinylestradiol (COC)	◆	■	■	◆	■
Testosterone	◆	◆	◆	◆	◆
Erectile Dysfunction Agents					
Sildenafil	◆	◆	◆	◆	◆
Tadalafil	◆	◆	◆	◆	◆
Vardenafil	◆	◆	◆	◆	◆
Yohimbine	◆	◆	◆	◆	◆

For personal use only. Not for distribution.

	BZF	ELA	OCA	SEL	UDCA
Gastrointestinal Agents					
Aluminium hydroxide	◆	◆	◆	◆	■
Alverine citrate	◆	◆	◆	◆	◆
Antacids	◆	◆	◆	◆	■
Aprepitant	◆	◆	◆	◆	◆
Bisacodyl	◆	◆	◆	◆	◆
Bismuth subsalicylate	◆	◆	◆	◆	◆
Cimetidine	◆	◆	◆	■	◆
Cisapride	◆	◆	▲	◆	▲
Cyclizine	◆	◆	◆	◆	◆
Dantron	◆	◆	◆	◆	◆
Docusate sodium	◆	◆	◆	◆	◆
Domperidone	◆	◆	◆	◆	◆
Droperidol	◆	◆	◆	◆	◆
Esomeprazole	◆	◆	◆	◆	◆
Famotidine	◆	◆	◆	◆	◆
Granisetron	◆	◆	◆	◆	◆
Hyoscine (Scopolamine)	◆	◆	◆	◆	◆
Hyoscine butylbromide	◆	◆	◆	◆	◆
Hyoscine hydrobromide (Scopolamine hydrobromide)	◆	◆	◆	◆	◆
Ispaghula husk	◆	◆	◆	◆	◆
Lactulose	◆	◆	◆	◆	◆
Lafutidine	◆	◆	◆	◆	◆
Lansoprazole	◆	◆	◆	◆	◆
Linaclotide	◆	◆	◆	◆	◆
Loperamide	◆	◆	◆	◆	◆
Lubiprostone	◆	◆	◆	◆	◆
Macrogol	▲	◆	▲	◆	▲
Mebeverine	◆	◆	◆	◆	◆
Mesalazine	◆	◆	◆	◆	◆
Methylcellulose	◆	◆	◆	◆	◆
Metoclopramide	◆	◆	◆	◆	◆
Naldemedine	◆	◆	◆	◆	◆
Naloxegol	◆	◆	◆	◆	◆
Nizatidine	◆	◆	◆	◆	◆
Omeprazole	◆	◆	◆	◆	◆
Ondansetron	◆	◆	◆	◆	◆
Pantoprazole	◆	◆	◆	◆	◆
Prucalopride	◆	◆	◆	◆	◆
Rabeprazole	◆	◆	▲	◆	◆
Ranitidine	◆	◆	◆	◆	◆
Roxatidine	◆	◆	◆	◆	◆
Senna	◆	◆	◆	◆	◆
Simeticone	◆	◆	◆	◆	◆
Sulfasalazine	◆	◆	◆	◆	◆
Trimebutine	◆	◆	◆	◆	◆
Vonoprazan	◆	◆	◆	◆	◆
HCC Therapies					
Atezolizumab + bevacizumab	■	◆	◆	◆	◆
Lenvatinib	◆	■	◆	◆	◆
Pembrolizumab	◆	◆	◆	◆	◆
Regorafenib	◆	◆	◆	■	◆
Sorafenib	◆	◆	◆	■	◆
Hepatitis B Drugs					
Adefovir	◆	◆	▲	◆	◆
Entecavir	◆	◆	◆	◆	◆
Lamivudine	◆	◆	◆	◆	◆
Peginterferon alfa-2a	◆	◆	◆	◆	◆
Peginterferon alfa-2b	◆	◆	◆	◆	◆
Ribavirin	◆	◆	◆	◆	◆
Telbivudine	■	■	◆	◆	◆
Tenofovir alafenamide	◆	◆	◆	◆	◆
Tenofovir-DF	◆	◆	◆	▲	◆
Hepatitis C Drugs					
Daclatasvir	◆	◆	◆	■	◆
Elbasvir/Grazoprevir	◆	◆	◆	■	◆
Glecaprevir/Pibrentasvir	◆	◆	◆	■	◆
Ledipasvir/Sofosbuvir	◆	◆	◆	■	◆
OBV/PTV/r	◆	◆	◆	■	◆
OBV/PTV/r + Dasabuvir	◆	◆	◆	■	◆
Ravidasvir	◆	◆	◆	■	◆
Ribavirin	◆	◆	◆	◆	◆
Sofosbuvir (SOF)	◆	◆	◆	◆	◆
SOF/Velpatasvir	◆	◆	◆	■	◆
SOF/Velpatasvir/Voxilaprevir	◆	◆	◆	■	◆
Hepatitis D Entry Inhibitors					
Bulevirtide	◆	◆	◆	◆	◆

For personal use only. Not for distribution.

Key to symbols

●	These drugs should not be coadministered
■	Potential clinically significant interaction that is likely to require additional monitoring, alteration of drug dosage or timing of administration
▲	Potential interaction likely to be of weak intensity. Additional action/monitoring or dosage adjustment is unlikely to be required
◆	No clinically significant interaction expected

Notes

- Further information is available at www.hep-druginteractions.org
- Predicted interactions are based on known metabolic pathways and routes of clearance.
- Caution is required in patients with hepatic impairment as this may also increase drug levels and require dose modification.
- Where advice differs between countries, the charts reflect the more cautious option.

© Liverpool Drug Interactions Group, Liverpool Drug Interactions Group, University of Liverpool, 3rd Floor William Henry Duncan Building, 6 West Derby Street, Liverpool, L7 8TX.
 We aim to ensure that information is accurate and consistent with current knowledge and practice. However, the University of Liverpool and its servants or agents shall not be responsible or in any way liable for the continued currency of information in this publication whether arising from negligence or otherwise howsoever or for any consequences arising therefrom. The University of Liverpool expressly exclude liability for errors, omissions or inaccuracies to the fullest extent permitted by law.

Interactions with PBC Agents

Please note that if a drug is not listed it cannot automatically be assumed it is safe to coadminister.

BZF; Bezafibrate, ELA, Elafibranol; OCA, Obeticholic Acid; SEL, Seladelpar; UDCA, Ursodeoxycholic Acid

	BZF	ELA	OCA	SEL	UDCA
Herbals/Supplements/Vitamins					
Aloe vera	◆	◆	◆	◆	◆
Ascorbic acid (Vitamin C)	◆	◆	◆	◆	◆
Ashwagandha (Withania somnifera)	◆	◆	◆	◆	◆
Black cohosh (A. racemosa)	◆	◆	◆	◆	◆
Calcium carbonate	◆	◆	◆	◆	◆
Cat's claw (U. tomentosa)	◆	◆	◆	◆	◆
Colecalciferol (Vitamin D3)	◆	◆	◆	◆	◆
Cyanocobalamin (B12)	◆	◆	◆	◆	◆
Diosmin	◆	◆	◆	◆	◆
Echinacea	◆	◆	◆	◆	◆
Enteral feeds	◆	◆	◆	◆	◆
Eucalyptus globulus	◆	◆	◆	◆	◆
Ferrous sulphate	◆	◆	◆	◆	◆
Folic acid	◆	◆	◆	◆	◆
Garlic	◆	◆	◆	◆	◆
Ginger (Z. officinale)	◆	◆	◆	◆	◆
Ginkgo biloba	◆	◆	◆	◆	◆
Ginseng	◆	◆	◆	◆	◆
Goldenseal (H. canadensis)	◆	◆	◆	◆	◆
Grape seed extract	◆	◆	◆	◆	◆
Grapefruit juice	◆	◆	◆	◆	◆
Green tea (C. sinensis)	◆	◆	◆	◆	◆
Homeopathic remedies	◆	◆	◆	◆	◆
Hydroxocobalamin (Vitamin B12)	◆	◆	◆	◆	◆
Inula racemosa	◆	◆	◆	◆	◆
Iodine	◆	◆	◆	◆	◆
Kava kava (P. methysticum)	◆	◆	◆	◆	◆
L-lysine	◆	◆	◆	◆	◆
Menthol	◆	◆	◆	◆	◆
Milk thistle	◆	◆	◆	◆	◆
Mucuna pruriens	◆	◆	◆	◆	◆
Niacin (Vitamin B3)	■	◆	◆	◆	◆
Oral nutritional supplements	◆	◆	◆	◆	◆
Oregano oil	◆	◆	◆	◆	◆
Pyridoxine (Vitamin B6)	◆	◆	◆	◆	◆
Retinol (Vitamin A)	◆	◆	◆	◆	◆
Riboflavin (Vitamin B2)	◆	◆	◆	◆	◆
Saw palmetto (S. repens)	◆	◆	◆	◆	◆
St John's wort	◆	■	◆	■	◆
Thiamine (Vitamin B1)	◆	◆	◆	◆	◆
Turmeric (curcumin)	◆	◆	◆	■	◆
Valerian	◆	◆	◆	◆	◆
Vitamin E	◆	◆	◆	◆	◆
Zinc	◆	◆	◆	◆	◆

For personal use only. Not for distribution.

	BZF	ELA	OCA	SEL	UDCA
HIV Drugs					
Entry/Integrase Inhibitors					
Albuvirtide	◆	◆	◆	◆	◆
Bictegravir/FTC/TAF	◆	◆	◆	◆	◆
Cabotegravir (oral)	◆	◆	◆	◆	◆
Cabotegravir/rilpivirine (LA)	◆	◆	◆	◆	■
Dolutegravir	◆	◆	◆	◆	◆
Dolutegravir/ABC/3TC	◆	◆	◆	◆	◆
Dolutegravir/3TC	◆	◆	◆	◆	◆
Dolutegravir/rilpivirine	◆	◆	◆	◆	■
Elvitegravir/cobi /FTC/TAF	◆	◆	◆	■	◆
Elvitegravir/cobi/FTC/TDF	◆	◆	◆	■	◆
Enfuvirtide	◆	◆	◆	◆	◆
Fostemsavir	◆	◆	◆	■	◆
Ibalizumab-uiyk	◆	◆	◆	◆	◆
Lenacapavir	◆	◆	◆	◆	●
Maraviroc	◆	◆	◆	◆	◆
Raltegravir	◆	◆	◆	◆	◆
NNRTIs					
Dapivirine	◆	◆	◆	◆	◆
Doravirine	◆	◆	◆	◆	◆
Doravirine/3TC/TDF	◆	◆	◆	▲	◆
Efavirenz	◆	■	◆	■	▲
Etravirine	◆	◆	◆	■	◆
Nevirapine	◆	■	◆	■	▲
Rilpivirine	◆	◆	◆	◆	■
Rilpivirine/FTC/TAF	◆	◆	◆	◆	■
NRTIs					
Abacavir	◆	◆	◆	◆	◆
Didanosine	◆	◆	◆	◆	◆
Emtricitabine (FTC)	◆	◆	◆	◆	◆
Emtricitabine + TAF	◆	◆	◆	◆	◆
Emtricitabine + TDF	◆	◆	◆	▲	◆
Lamivudine	◆	◆	◆	◆	◆
Stavudine	◆	◆	◆	◆	◆
Tenofovir-DF	◆	◆	◆	▲	◆
Zidovudine	■	◆	◆	◆	◆
Protease Inhibitors					
Atazanavir + ritonavir	◆	◆	■	■	◆
Atazanavir alone	◆	◆	■	◆	◆
Atazanavir/cobicistat	◆	◆	■	■	◆
Darunavir + ritonavir	◆	◆	■	■	◆
Darunavir/cobicistat	◆	◆	■	■	◆
Darunavir/cobi/FTC/TAF	◆	◆	■	■	◆
Fosamprenavir	◆	◆	■	■	◆
Indinavir	◆	◆	■	■	▲
Lopinavir	◆	◆	■	■	▲
Ritonavir	◆	◆	■	■	◆
Tipranavir	◆	◆	■	■	▲

For personal use only. Not for distribution.

Key to symbols

●	These drugs should not be coadministered
■	Potential clinically significant interaction that is likely to require additional monitoring, alteration of drug dosage or timing of administration
▲	Potential interaction likely to be of weak intensity. Additional action/monitoring or dosage adjustment is unlikely to be required
◆	No clinically significant interaction expected

Notes

- Further information is available at www.hep-druginteractions.org
- Predicted interactions are based on known metabolic pathways and routes of clearance.
- Caution is required in patients with hepatic impairment as this may also increase drug levels and require dose modification.
- Where advice differs between countries, the charts reflect the more cautious option.

© Liverpool Drug Interactions Group, Liverpool Drug Interactions Group, University of Liverpool, 3rd Floor William Henry Duncan Building, 6 West Derby Street, Liverpool, L7 8TX.
 We aim to ensure that information is accurate and consistent with current knowledge and practice. However, the University of Liverpool and its servants or agents shall not be responsible or in any way liable for the continued currency of information in this publication whether arising from negligence or otherwise howsoever or for any consequences arising therefrom. The University of Liverpool expressly exclude liability for errors, omissions or inaccuracies to the fullest extent permitted by law.

Interactions with PBC Agents

Please note that if a drug is not listed it cannot automatically be assumed it is safe to coadminister.

BZF; Bezafibrate, ELA, Elafibranol; OCA, Obeticholic Acid; SEL, Seladelpar; UDCA, Ursodeoxycholic Acid

	BZF	ELA	OCA	SEL	UDCA
Hypertension/Heart Failure Agents					
Acebutolol	◆	◆	◆	◆	◆
Aliskiren	◆	◆	◆	◆	◆
Ambrisentan	◆	◆	◆	◆	◆
Amiloride	◆	◆	◆	◆	◆
Azilsartan	◆	◆	◆	◆	◆
Benazepril	◆	◆	◆	◆	◆
Bendroflumethiazide	◆	◆	◆	◆	◆
Bosentan	◆	◆	■	■	▲
Bumetanide	◆	◆	◆	◆	◆
Candesartan	◆	◆	■	◆	◆
Captopril	◆	◆	◆	◆	◆
Chlorothiazide	◆	◆	◆	◆	◆
Chlortalidone	◆	◆	◆	◆	◆
Cilazapril	◆	◆	◆	◆	◆
Clevidipine	◆	◆	◆	◆	◆
Clonidine	◆	◆	◆	◆	◆
Doxazosin	◆	◆	▲	◆	◆
Enalapril	◆	◆	◆	◆	◆
Eplerenone	◆	◆	◆	◆	◆
Epoprostenol	◆	◆	◆	◆	◆
Eprosartan	◆	◆	◆	◆	◆
Fosinopril	◆	◆	◆	◆	◆
Furosemide	◆	◆	◆	◆	◆
Hydralazine	◆	◆	◆	◆	◆
Hydrochlorothiazide	◆	◆	◆	◆	◆
Iloprost	◆	◆	◆	◆	◆
Indapamide	◆	◆	◆	◆	◆
Irbesartan	◆	◆	■	◆	◆
Isradipine	◆	◆	▲	◆	▲
Ivabradine	◆	◆	◆	◆	◆
Lacidipine	◆	◆	◆	◆	▲
Lercanidipine	◆	◆	◆	◆	▲
Lisinopril	◆	◆	◆	◆	◆
Losartan	◆	◆	■	◆	◆
Macitentan	◆	◆	◆	◆	◆
Methyldopa	◆	◆	◆	◆	◆
Metolazone	◆	◆	◆	◆	◆
Moxonidine	◆	◆	◆	◆	◆
Olmesartan	◆	◆	■	◆	◆
Perindopril	◆	◆	◆	◆	◆
Prazosin	◆	◆	◆	◆	◆
Quinapril	◆	◆	▲	◆	◆
Ramipril	◆	◆	◆	◆	◆
Ranolazine	◆	◆	▲	◆	▲
Rilmenidine	◆	◆	◆	◆	◆
Riociguat	◆	◆	◆	◆	◆
Sacubitril/valsartan	◆	◆	◆	◆	◆
Selexipag	◆	◆	◆	◆	▲
Sildenafil	◆	◆	◆	◆	◆
Sodium nitroprusside	◆	◆	◆	◆	◆
Spironolactone	◆	◆	■	◆	◆
Tadalafil	◆	◆	◆	◆	◆
Telmisartan	◆	◆	■	◆	◆
Torasemide	◆	◆	◆	◆	◆
Trandolapril	◆	◆	◆	◆	◆
Treprostinil	◆	◆	◆	◆	▲
Valsartan	◆	◆	◆	◆	◆
Xipamide	◆	◆	◆	◆	◆
Zofenopril	◆	◆	◆	◆	◆

For personal use only. Not for distribution.

	BZF	ELA	OCA	SEL	UDCA
Illicit/Recreational					
Alcohol	◆	◆	◆	◆	◆
Amphetamine	◆	◆	◆	◆	▲
Bromazolam	◆	◆	◆	◆	◆
Cannabis	◆	◆	◆	◆	◆
Carfentanil	◆	◆	◆	◆	◆
Cocaine	◆	◆	◆	◆	◆
Ecstasy (MDMA)	◆	◆	◆	◆	▲
Etizolam	◆	◆	◆	◆	◆
Fentanyl (Recreational)	◆	◆	◆	◆	◆
GHB (Gamma-hydroxybutyrate)	◆	◆	◆	◆	◆
Heroin	◆	◆	◆	◆	◆
Ketamine	◆	◆	◆	◆	◆
LSD (Lysergic acid diethylamide)	◆	◆	◆	◆	▲
Mephedrone	◆	◆	◆	◆	▲
Methamphetamine	◆	◆	◆	◆	▲
Nicotine	◆	◆	◆	◆	◆
Nitazenes	◆	◆	▲	◆	◆
Nitrous oxide	◆	◆	◆	◆	◆
Phencyclidine (PCP)	◆	◆	◆	◆	▲
Xylazine	◆	◆	▲	◆	◆
Immunosuppressants					
Abatacept	◆	◆	◆	◆	◆
Adalimumab	◆	◆	◆	◆	◆
Alemtuzumab	◆	◆	◆	◆	◆
Anakinra	◆	◆	◆	◆	◆
Apremilast	◆	◆	◆	◆	◆
Azathioprine	◆	◆	◆	◆	◆
Baricitinib	◆	◆	◆	◆	◆
Basiliximab	◆	◆	◆	◆	◆
Belimumab	◆	◆	◆	◆	◆
Brodalumab	◆	◆	◆	◆	◆
Canakinumab	◆	◆	◆	◆	◆
Ciclosporin	■	◆	■	■	■
Cladribine (oral)	◆	■	◆	◆	◆
Eculizumab	◆	◆	◆	◆	◆
Etanercept	◆	◆	◆	◆	◆
Fingolimod	◆	◆	◆	◆	◆
Golimumab	◆	◆	◆	◆	◆
Guselkumab	◆	◆	◆	◆	◆
Infliximab	◆	◆	◆	◆	◆
Ixekizumab	◆	◆	◆	◆	◆
Lenalidomide	◆	◆	◆	◆	◆
Mirikizumab	◆	◆	◆	◆	◆
Mycophenolate	◆	◆	▲	◆	◆
Pirfenidone	◆	◆	◆	◆	◆
Ravulizumab	◆	◆	◆	◆	◆
Risankizumab	◆	◆	◆	◆	◆
Sarilumab	◆	◆	◆	◆	◆
Secukinumab	◆	◆	◆	◆	◆
Siltuximab	◆	◆	◆	◆	◆
Sirolimus	◆	◆	◆	◆	▲
Tacrolimus	■	◆	■	◆	▲
Tildrakizumab	◆	◆	◆	◆	◆
Tocilizumab	◆	◆	◆	◆	◆
Tralokinumab	◆	◆	◆	◆	◆
Ublituximab	◆	◆	◆	◆	◆
Upadacitinib	◆	◆	◆	◆	◆
Ustekinumab	◆	◆	◆	◆	◆
Vedolizumab	◆	◆	◆	◆	◆

For personal use only. Not for distribution.

Key to symbols

●	These drugs should not be coadministered
■	Potential clinically significant interaction that is likely to require additional monitoring, alteration of drug dosage or timing of administration
▲	Potential interaction likely to be of weak intensity. Additional action/monitoring or dosage adjustment is unlikely to be required
◆	No clinically significant interaction expected

Notes

- Further information is available at www.hep-druginteractions.org
- Predicted interactions are based on known metabolic pathways and routes of clearance.
- Caution is required in patients with hepatic impairment as this may also increase drug levels and require dose modification.
- Where advice differs between countries, the charts reflect the more cautious option.

© Liverpool Drug Interactions Group,
 Liverpool Drug Interactions Group, University of Liverpool, 3rd Floor William Henry Duncan Building, 6 West Derby Street, Liverpool, L7 8TX.
 We aim to ensure that information is accurate and consistent with current knowledge and practice. However, the University of Liverpool and its servants or agents shall not be responsible or in any way liable for the continued currency of information in this publication whether arising from negligence or otherwise howsoever or for any consequences arising therefrom. The University of Liverpool expressly exclude liability for errors, omissions or inaccuracies to the fullest extent permitted by law.

Interactions with PBC Agents

Please note that if a drug is not listed it cannot automatically be assumed it is safe to coadminister.

BZF; Bezafibrate, ELA, Elafibranor; OCA, Obeticholic Acid; SEL, Seladelpar; UDCA, Ursodeoxycholic Acid

	BZF	ELA	OCA	SEL	UDCA
Lipid Lowering Agents					
Alirocumab	◆	◆	◆	◆	◆
Atorvastatin	■	■	■	◆	◆
Bempedoic acid	◆	▲	◆	▲	▲
Evolocumab	◆	◆	◆	◆	◆
Ezetimibe	◆	◆	▲	◆	◆
Fenofibrate	●	●	■	◆	◆
Fish oils	◆	◆	◆	◆	◆
Fluvastatin	■	■	▲	◆	◆
Gemfibrozil	■	▲	◆	■	◆
Icosapent ethyl	◆	◆	◆	◆	▲
Lovastatin	■	■	■	◆	◆
Omega-3-6-9 fatty acids	◆	◆	◆	◆	◆
Pitavastatin	■	■	■	◆	◆
Pravastatin	■	■	◆	◆	◆
Rosuvastatin	■	■	◆	◆	◆
Simvastatin	■	■	■	◆	◆
Oxytocics					
Ergometrine (ergonovine)	◆	◆	◆	◆	◆
Mifepristone	◆	◆	■	■	◆
Misoprostol	◆	◆	▲	◆	◆
Parkinsonism Agents					
Benzatropine (Benztropine)	◆	◆	◆	◆	▲
Carbidopa	◆	◆	◆	◆	◆
Levodopa	■	◆	◆	◆	◆
Orphenadrine	◆	◆	◆	◆	▲
Pramipexole	◆	◆	◆	◆	▲
Procyclidine	◆	◆	◆	◆	◆
Rasagiline	▲	◆	◆	◆	▲
Ropinirole	◆	◆	◆	◆	▲
Selegiline	▲	◆	◆	◆	◆
Trihexyphenidyl	◆	◆	◆	◆	▲
PBC Agents					
Bezafibrate	◆	●	◆	◆	◆
Elafibranor	●	◆	◆	▲	◆
Obeticholic acid	◆	◆	◆	◆	◆
Seladelpar	◆	▲	◆	◆	◆
Ursodeoxycholic acid	◆	◆	◆	◆	◆
Steroids					
Beclomethasone	◆	◆	◆	◆	◆
Betamethasone	■	◆	◆	◆	◆
Budesonide	■	◆	▲	◆	◆
Ciclesonide	◆	◆	◆	◆	◆
Clobetasol (topical)	◆	◆	◆	◆	◆
Clobetasone (topical)	◆	◆	◆	◆	◆
Dexamethasone ≤ 16 mg	■	◆	◆	◆	▲
Dexamethasone >16 mg	■	◆	◆	■	▲
Fludrocortisone	■	◆	◆	◆	◆
Flunisolide	◆	◆	◆	◆	◆
Fluticasone	◆	◆	◆	◆	◆
Hydrocortisone (topical)	◆	◆	◆	◆	◆
Methylprednisolone	■	◆	◆	◆	◆
Mometasone	◆	◆	◆	◆	◆
Prednicarbate	◆	◆	◆	◆	◆
Prednisone	■	◆	◆	◆	◆
Triamcinolone	■	◆	◆	◆	◆
Urological Agents					
Alfuzosin	◆	◆	◆	◆	◆
Desmopressin	◆	◆	◆	◆	◆
Dutasteride	◆	◆	▲	◆	◆
Finasteride	◆	◆	▲	◆	◆
Mirabegron	◆	◆	◆	◆	◆
Oxybutynin	◆	◆	◆	◆	▲
Propiverine	◆	◆	◆	◆	▲
Silodosin	◆	◆	◆	◆	◆
Solifenacin	◆	◆	◆	◆	◆
Tamsulosin	◆	◆	◆	◆	◆
Tolterodine	◆	◆	◆	◆	◆
Trospium	◆	◆	◆	◆	◆

For personal use only. Not for distribution.

	BZF	ELA	OCA	SEL	UDCA
Other Drugs					
Acamprosate	◆	◆	◆	◆	◆
Acetazolamide	◆	◆	◆	◆	◆
Acitretin	◆	◆	▲	◆	◆
Activated charcoal	◆	◆	▲	▲	▲
Allopurinol	◆	◆	◆	◆	◆
Atomoxetine	◆	◆	◆	◆	◆
Atropine	◆	◆	◆	◆	◆
Baclofen	◆	◆	◆	◆	◆
Bamlanivimab/ Etesevimab	◆	◆	◆	◆	◆
Benralizumab	◆	◆	◆	◆	◆
Bethahistine	◆	◆	◆	◆	◆
Bimatoprost	◆	◆	◆	◆	◆
Biperiden	◆	◆	◆	◆	▲
Brimonidine	◆	◆	◆	◆	◆
Brinzolamide	◆	◆	◆	◆	◆
Brolucizumab	◆	◆	◆	◆	◆
Bromocriptine	◆	◆	◆	◆	◆
Burosumab	◆	◆	◆	◆	◆
Calcitonin	◆	◆	◆	◆	◆
Calcium carbimide	◆	◆	◆	◆	◆
Calcium resonium	◆	◆	◆	◆	◆
Cannabidiol (CBD)	◆	◆	◆	◆	◆
Carbamazole	◆	◆	◆	◆	◆
Carisoprodol	◆	◆	◆	◆	▲
Casirivimab/Imdevimab	◆	◆	◆	◆	◆
Cilostazol	◆	◆	◆	◆	◆
Clomifene	◆	◆	◆	◆	◆
Colchicine	■	◆	◆	◆	◆
Colestyramine	▲	■	■	■	■
Conivaptan	◆	◆	◆	◆	◆
COVID-19 vaccines	◆	◆	◆	◆	◆
Cyclobenzaprine	◆	◆	◆	◆	▲
Cyproterone acetate	◆	◆	◆	◆	◆
Cytisine	◆	◆	◆	◆	◆
Darbepoetin	◆	◆	◆	◆	◆
Deferiprone	◆	◆	◆	◆	◆
Delgocitinib	◆	◆	◆	◆	◆
Denosumab	◆	◆	◆	◆	◆
Dexamfetamine	◆	◆	◆	◆	▲
Dextromethorphan	◆	◆	◆	◆	◆
Disulfiram	◆	◆	▲	◆	▲
Donepezil	◆	◆	◆	◆	◆
Dorzolamide	◆	◆	◆	◆	◆
Dotinurad	◆	◆	◆	◆	◆
Dupilumab	◆	◆	◆	◆	◆
Eliquis	◆	◆	◆	◆	◆
Emicizumab	◆	◆	◆	◆	◆
Epoetin alfa	◆	◆	◆	◆	◆
Etelcalcetide	◆	◆	◆	◆	◆
Faricimab	◆	◆	◆	◆	◆
Febuxostat	◆	◆	▲	■	◆
Filgrastim	◆	◆	◆	◆	◆
Flibanserin	◆	◆	◆	◆	▲
Gadopentetate (gadolinium)	◆	◆	◆	◆	◆
Glucose monohydrate (IV)	◆	◆	◆	◆	◆
Glycerol phenylbutyrate	◆	◆	◆	◆	◆
Goserelin acetate	◆	◆	◆	◆	◆
Guanfacine	◆	◆	◆	◆	◆
Idarucizumab	◆	◆	◆	◆	◆
Influenza vaccine	◆	◆	◆	◆	◆
Interferon beta	◆	◆	◆	◆	◆
Isoorbide mononitrate	◆	◆	◆	◆	◆
Isotretinoin	◆	◆	▲	◆	▲
Lanadelumab	◆	◆	◆	◆	◆
Lanreotide	◆	◆	◆	◆	◆
Lisdexamfetamine	◆	◆	◆	◆	◆
Lebrikizumab	◆	◆	◆	◆	◆
Lecanemab	◆	◆	◆	◆	◆
Leuprorelin acetate	◆	◆	◆	◆	◆
Levothyroxine	◆	◆	◆	◆	◆
Lisdexamfetamine	◆	◆	◆	◆	◆
Lofexidine	◆	◆	◆	◆	◆
Lumacaftor/Ivacaftor	◆	■	◆	■	◆
Magnesium	◆	◆	◆	◆	◆
Maralixibat	◆	◆	◆	◆	◆
Melatonin	◆	◆	◆	◆	◆
Memantine	◆	◆	◆	◆	▲

For personal use only. Not for distribution.

Key to symbols

●	These drugs should not be coadministered
■	Potential clinically significant interaction that is likely to require additional monitoring, alteration of drug dosage or timing of administration
▲	Potential interaction likely to be of weak intensity. Additional action/monitoring or dosage adjustment is unlikely to be required
◆	No clinically significant interaction expected

Notes

- Further information is available at www.hep-druginteractions.org
- Predicted interactions are based on known metabolic pathways and routes of clearance.
- Caution is required in patients with hepatic impairment as this may also increase drug levels and require dose modification.
- Where advice differs between countries, the charts reflect the more cautious option.

© Liverpool Drug Interactions Group,
 Liverpool Drug Interactions Group, University of Liverpool, 3rd Floor William Henry Duncan Building, 6 West Derby Street, Liverpool, L7 8TX.
 We aim to ensure that information is accurate and consistent with current knowledge and practice. However, the University of Liverpool and its servants or agents shall not be responsible or in any way liable for the continued currency of information in this publication whether arising from negligence or otherwise howsoever or for any consequences arising therefrom. The University of Liverpool expressly exclude liability for errors, omissions or inaccuracies to the fullest extent permitted by law.

Interactions with PBC Agents

Please note that if a drug is not listed it cannot automatically be assumed it is safe to coadminister.

BZF; Bezafibrate, ELA, Elafibranor; OCA, Obeticholic Acid; SEL, Seladelpar; UDCA, Ursodeoxycholic Acid

Other Drugs Continued	BZF	ELA	OCA	SEL	UDCA
Mepolizumab	◆	◆	◆	◆	◆
Methimazole (Thiamazole)	◆	◆	◆	◆	◆
Methylphenidate	◆	◆	◆	◆	◆
Midodrine	◆	◆	◆	◆	◆
Minoxidil	◆	◆	◆	◆	◆
Modafinil	◆	◆	◆	■	◆
Nafidrofuryl	◆	◆	◆	◆	◆
Nalmefene	◆	▲	◆	◆	◆
Naloxone	◆	◆	◆	◆	◆
Naltrexone	◆	◆	◆	◆	◆
Neostigmine	◆	◆	◆	◆	◆
Nicorandil	◆	◆	◆	◆	◆
Nusinersen	◆	◆	◆	◆	◆
Ocrelizumab	◆	◆	◆	◆	◆
Orlistat	◆	◆	▲	▲	▲
Pancreatic enzymes	◆	◆	◆	◆	◆
Penicillamine	■	◆	◆	◆	◆
Pentoxifylline	◆	◆	◆	◆	◆
Phentermine	◆	◆	◆	◆	◆
Phenylephrine	◆	◆	◆	◆	◆
Pilocarpine	◆	◆	◆	◆	◆
Piracetam	◆	◆	◆	◆	◆
Potassium	◆	◆	◆	◆	◆
Propylthiouracil	◆	◆	◆	◆	◆
Protamine sulphate	◆	◆	◆	◆	◆
Pseudoephedrine	◆	◆	◆	◆	◆
Pyridostigmine	◆	◆	◆	◆	◆
Raloxifene	◆	◆	◆	◆	◆
Romozozumab	◆	◆	◆	◆	◆
Rozanolixizumab	◆	◆	◆	◆	◆
Selegiline	◆	◆	◆	◆	◆
Sevelamer	◆	▲	▲	▲	▲
Sodium zirconium cyclosilicate	◆	◆	◆	◆	◆
Strontium ranelate	◆	◆	◆	◆	◆
Tetrabenazine	◆	◆	▲	◆	▲
Thalidomide	◆	◆	◆	◆	◆
Triptorelin	◆	◆	◆	◆	◆
Tranexamic acid	◆	◆	◆	◆	◆
Varenicline	◆	◆	◆	◆	◆

For personal use only. Not for distribution.

For personal use only. Not for distribution.

Using a saved or printed version? Click or scan to check for updates.

Key to symbols

●	These drugs should not be coadministered
■	Potential clinically significant interaction that is likely to require additional monitoring, alteration of drug dosage or timing of administration
▲	Potential interaction likely to be of weak intensity. Additional action/monitoring or dosage adjustment is unlikely to be required
◆	No clinically significant interaction expected

Notes

- Further information is available at www.hep-druginteractions.org
- Predicted interactions are based on known metabolic pathways and routes of clearance.
- Caution is required in patients with hepatic impairment as this may also increase drug levels and require dose modification.
- Where advice differs between countries, the charts reflect the more cautious option.

© Liverpool Drug Interactions Group, Liverpool Drug Interactions Group, University of Liverpool, 3rd Floor William Henry Duncan Building, 6 West Derby Street, Liverpool, L7 8TX.
 We aim to ensure that information is accurate and consistent with current knowledge and practice. However, the University of Liverpool and its servants or agents shall not be responsible or in any way liable for the continued currency of information in this publication whether arising from negligence or otherwise howsoever or for any consequences arising therefrom. The University of Liverpool expressly exclude liability for errors, omissions or inaccuracies to the fullest extent permitted by law.